Figure 3: LPH nanoparticles composed of PolyMet can systemically deliver VEGF siRNA to the tumour site and inhibit tumour growth.
From: PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery
(a) H460 tumour-bearing mice were injected i.v. every other day and tumour volumes were measured every day. (b) H460 tumour VEGF protein levels after two injections were measured by western blot analysis. Bar chart in b represent quantitative analysis of relative normalized VEGF band intensity (Image J). (c) TUNEL staining (green) in H460 tumour cells after treatment with siRNA in different formulations in vivo. Nucleic acid was stained with 4,6-diamidino-2-phenylindole (blue). Bar chart in c is a quantitative analysis of % of TUNEL-positive cells. Five randomly selected microscopic fields were quantitatively analysed on Image J. Data are mean±s.e.m. (n=5 per group) analysed by two-way analysis of variance with Tukey’s correction. Data are representative of b and c or combined from (a) three independent experiments. NS, not significant; *P<0.05, **P<0.01, ***P<0.005. Scale bar, 200 μm.
